Tumor tracking device cleared for use in post-RP patients

May 20, 2008

FDA has cleared the use of the implantable Beacon electromagnetic transponders with Calypso Medical's Calypso System in external beam radiation therapy for post-prostatectomy patients. Previously, the system (known as "GPS for the Body") was cleared solely for use in patients with an intact prostate.

FDA has cleared the use of the implantable Beacon electromagnetic transponders with Calypso Medical's Calypso System in external beam radiation therapy for post-prostatectomy patients. Previously, the system (known as "GPS for the Body") was cleared solely for use in patients with an intact prostate.

The system uses tiny transponders to set up and continuously track the position of targeted tissue during radiation treatment. In the event that the tumor site moves outside of acceptable limits, the clinician adapts therapy during daily treatment to ensure the treatment is delivered as prescribed to the cancerous tissue while avoiding adjacent healthy organs.

The technology platform is designed to provide objective, accurate, and continuous tracking information during external beam radiation therapy without adding ionizing radiation, according to Calypso.